Global Radioligand Therapy Market Growth (Status and Outlook) 2025-2031

The global Radioligand Therapy market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

United States market for Radioligand Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Radioligand Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Radioligand Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Radioligand Therapy players cover Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Radioligand Therapy Industry Forecast” looks at past sales and reviews total world Radioligand Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Radioligand Therapy sales for 2025 through 2031. With Radioligand Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radioligand Therapy industry.

This Insight Report provides a comprehensive analysis of the global Radioligand Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radioligand Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radioligand Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radioligand Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radioligand Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Radioligand Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Actinium 225 (Ac-225)
Lutetium 177 (Lu-177)
Gallium 68 (Ga-68)
Fluorine 18 (F-18)
Other Radionuclides

Segmentation by Application:
Neuroendocrine Neoplasms
Prostate Cancer

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix

Please note: The report will take approximately 2 business days to prepare and deliver.